不同月龄婴幼儿接种F基因型腮腺炎减毒活疫苗的免疫应答研究
|
摘要
目的探索不同月龄婴幼儿接种F基因型腮腺炎减毒活疫苗(Mumps attenuated live vaccine, MuV)后的免疫应答差异。方法招募无流行性腮腺炎疾病史且未接种过含腮腺炎成分疫苗的8-24月龄健康婴幼儿,接种F基因型MuV,采集免疫前和免疫后28d血标本,检测抗F基因型腮腺炎病毒中和抗体。结果分别招募8-12月龄、13-17月龄、18-24月龄健康儿童132名、104名、99名。3个年龄组儿童MuV免疫后抗F基因型腮腺炎病毒中和抗体阳性率分别为88.6%、90.4%、90.9%(χ~2=0.37,P=0.832),阳转率分别为87.9%、89.4%、89.9%(χ~2=0.27,P=0.874),几何平均滴度分别为1:5.88、1:7.12、1:6.83(H=1.25,P=0.536)。结论不同月龄婴幼儿接种F基因型MuV后均有良好免疫应答。
Objective To determine the age-specific immune response to vaccination of children with an F genotype live attenuated mumps vaccine(MuV). Methods We recruited as study subjects 8-24-month-old healthy children who had not had mumps illness and had not received mumps vaccine, and offered an F genotype MuV to those who participated. We collected blood samples before and28 days after vaccination to test for neutralizing antibody against an F genotype mumps virus. Results We recruited 132, 104, and 99 children aged 8-12, 13-17, and 18-24 months, respectively. Post-vaccination positivity rates of neutralizing antibody were 88.6%, 90.4%,and 90.9%(χ~2=0.37, P=0.832) for the three age groups; seroconversion rates were 87.9%, 89.4%, and 89.9%(χ~2=0.27, P=0.874); and geometric mean titers were 1:5.88, 1:7.12, and 1:6.83(H=1.25, P=0.536). Conclusions Vaccination of 8-24-month-old children with an F genotype MuV showed a good immune response, regardless of vaccination age.
Objective To determine the age-specific immune response to vaccination of children with an F genotype live attenuated mumps vaccine(MuV). Methods We recruited as study subjects 8-24-month-old healthy children who had not had mumps illness and had not received mumps vaccine, and offered an F genotype MuV to those who participated. We collected blood samples before and28 days after vaccination to test for neutralizing antibody against an F genotype mumps virus. Results We recruited 132, 104, and 99 children aged 8-12, 13-17, and 18-24 months, respectively. Post-vaccination positivity rates of neutralizing antibody were 88.6%, 90.4%,and 90.9%(χ~2=0.37, P=0.832) for the three age groups; seroconversion rates were 87.9%, 89.4%, and 89.9%(χ~2=0.27, P=0.874); and geometric mean titers were 1:5.88, 1:7.12, and 1:6.83(H=1.25, P=0.536). Conclusions Vaccination of 8-24-month-old children with an F genotype MuV showed a good immune response, regardless of vaccination age.
引文
[1]杨绍基,任红.传染病学[M].第7版.北京:人民卫生出版社,2010:79.YANG Shaoji,REN Hong.Infectious diseases[M].7th edition.Beijing:People's Medical Publishing House,2010:79.
[2]中华人民共和国国家卫生和计划生育委员会.国家免疫规划疫苗儿童免疫程序及说明(2016年版)[S].2016-12-06.National Health and Family Planning Commission of the People′s Republic of China.Immunization schedules and instructions for vaccines of the national immunization program(2016 version)[S].2016-12-06.
[3]中国生物技术有限公司.麻疹腮腺炎风疹联合减毒活疫苗[EB/OL].http://www.cnbg.com.cn/html/product/show_328.html.China National Biotec Group Company Limited.Measles,mumps and rubella combined vaccine,live[EB/OL].http://www.cnbg.com.cn/html/product/show_328.html.
[4]中国生物技术有限公司.麻疹腮腺炎联合减毒活疫苗[EB/OL].http://www.cnbg.com.cn/html/product/show_586.html.China National Biotec Group Company Limited.Measles and mumps combined vaccine,live[EB/OL].http://www.cnbg.com.cn/html/product/show_586.html.
[5]陈洁,陈深侠,凌罗亚,等.国产麻疹流行性腮腺炎风疹联合疫苗初免效果及免疫程序探讨[J].中国计划免疫,2006,12(3):215-217.CHEN Jie,CHEN Shenxia,LING Luoya,et al.Invest igat ion on immunogenici ty and immunizat ion procedure of China-made live attenuated measles-mumpsrubella combined vaccine[J].Chinese Journal of Vaccines and Immunization,2006,12(3):215-217.
[6]储艳,陆玉忠,陶红,等.国产麻腮风联合减毒活疫苗的安全性及免疫原性[J].中国生物制品学杂志,2011,24(6):707-710.CHU Yan,LU Yuzhong,TAO Hong,et al.Saf ety and immunogenicity of domestic combined live attenuated measles,mumps and rubella vaccine[J].Chinese Journal of Biologicals,2011,24(6):707-710.
[7]邵茜,朱梦蓉,刘鹏,等.8月龄首剂接种国产麻疹腮腺炎风疹联合减毒活疫苗的安全性及免疫原性观察[J].预防医学情报杂志,2016,32(7):742-746.SHAO Xi,ZHU Mengrong,LIU Peng et al,et al.Saf ety and immunogenicity of domestic combined live attenuated measles,mumps and rubel la vaccine in jected wi th8-month infants at the first dose[J].Journal of Preventive Medicine Information,2016,32(7):742-746.
[8]刘国华,方悍华,冯子健,等.冻干麻疹-腮腺炎-风疹三联活疫苗免疫安全性及免疫学效果观察[J].中华流行病学杂志,2002,23(6):435-437.LIU Guohua,FANG Hanhua,FENG Zijian,et al.Studies on the saf ety and immunogenicity oflyophilized live attenuated measles-mumps-rubella combined vaccine[J].Chinese Journal of Epidemiology,2002,23(6):435-437.
[9]俞柳燕,陈深侠,凌罗亚,等.8月龄儿童接种麻疹-腮腺炎-风疹三联疫苗免疫效果及接种安全性观察[J].中国预防医学杂志,2008,9(3):206-207.YU Liuyan,CHEN Shen xia,LING Luoya,et al.Observat ion on immunizat ion ef fect and saf e ty of measles-mumps-rubella triple vaccine for children aged 8months[J].China Preventive Medicine,2008,9(3):206-207.
[10]徐福根,陈康凯,黄利明,等.麻腮风(MMR)疫苗初免效果和程序的研究[J].浙江预防医学,2000,12(11):1-3.XU Fugen,CHEN Kangkai,HUANG Liming,et al.Study on the primary immunization ef fect and procedure of measles-mumps-rubella(MMR)vaccine[J].Zhe jiang Journal of Preventive Medicine,2000,12(11):1-3.
[11]徐福根,许二萍,黄诚孝,等.不同月龄婴儿接种腮腺炎疫苗的免疫效果比较[J].中国生物制品学杂志,2000,13(2):71.XU Fugen,XU Er ping,HUANG Chengx iao,et al.Comparison ofimmune effects of mumps vaccination in infants of different months of age[J].Chinese Journal of Biologicals,2000,13(2):71.
[12]杨秀惠,吴根生,周勇,等.福建省流行性腮腺炎疫苗免疫效果分析及程序探讨[J].海峡预防医学杂志,2015,21(6):17-20.YANG Xiuhui,WU Gensheng,ZHOU Yong,et al.Analysis of the immunization effect of mumps vaccine in Fujian province and discussion on the procedure[J].St rai t Journal of Preventive Medicine,2015,21(6):17-20.
[13]JIN L,ORVELL C,MYERS R,et al.Genomic diversity of mumps virus and global distribution of the 12 genotypes[J].Reviews in Medical Virology,2015,25(2):85-101.
[14]RUBIN SA,LINK MA,SAUDER CJ,et al.Recent mumps outbreaks in vaccinated populat ions:no evidence ofimmune escape[J].Journal of Virology,2012,86(1):615.
[15]CUI A,RIVAILLER P,ZHU Z,et al.Evolutionary analysis of mumps viruses of genotype F collected in mainland China in 2001-2015[J].Scientific Repor ts,2017,7(1):17144.
[16]CUI A,ZHU Z,HU Y,et al.Mumps epidemiology and mumps virus genotypes circulating in mainland China during 2013-2015[J].PloS One,2017,12(1):e0169561.
[17]VAIDYA SR,DVIVEDI GM,JADHAV SM.Cr ossneutralization between three mumps viruses&mapping of haemagglutinin-neuraminidase(HN)epitopes[J].Indian Journal of Medical Research,2016,143(1):37-42.
[18]GOUMA S,TEN HULSCHER HI,TM SK,et al.Mumpsspecific cross-neutralization by MMR vaccine-induced ant ibodies predicts protect ion against mumps vi rus infection[J].Vaccine,2016,34(35):4166-4171.
[19]ATCHAREEYA AN,PRAKONG S,SA-NGASANG A,et al.Comparison between haemagglutination inhibition(HI)test and IgM and IgG-capture ELISA in determination of primary and secondary dengue virus infections[J].Dengue Bulletin,2006,30:141-145.
[20]陈康凯,闻洪根,王衡.腮腺炎抗体测定血凝抑制法与酶联法的比较[J].预防医学情报杂志,2001,17(3):205-206.CHEN Kangkai,WEN Honggen,WANG Heng.Comparison of hemagglutination inhibition assay and enzyme-linked assay for detection of mumps antibody[J].Journal of Preventive Medicine Information,2001,17(3):205-206.
[21]NURHAYATI L,GUSTIANI S,HERMAN K,et al.Comparison of the hemagglutination inhibition test and IgG ELISA in categorizing primary and secondary dengue infections based on the plaque reduction neutralization test[J].BioMed Research International,2016,2016(1):5253842.
[2]中华人民共和国国家卫生和计划生育委员会.国家免疫规划疫苗儿童免疫程序及说明(2016年版)[S].2016-12-06.National Health and Family Planning Commission of the People′s Republic of China.Immunization schedules and instructions for vaccines of the national immunization program(2016 version)[S].2016-12-06.
[3]中国生物技术有限公司.麻疹腮腺炎风疹联合减毒活疫苗[EB/OL].http://www.cnbg.com.cn/html/product/show_328.html.China National Biotec Group Company Limited.Measles,mumps and rubella combined vaccine,live[EB/OL].http://www.cnbg.com.cn/html/product/show_328.html.
[4]中国生物技术有限公司.麻疹腮腺炎联合减毒活疫苗[EB/OL].http://www.cnbg.com.cn/html/product/show_586.html.China National Biotec Group Company Limited.Measles and mumps combined vaccine,live[EB/OL].http://www.cnbg.com.cn/html/product/show_586.html.
[5]陈洁,陈深侠,凌罗亚,等.国产麻疹流行性腮腺炎风疹联合疫苗初免效果及免疫程序探讨[J].中国计划免疫,2006,12(3):215-217.CHEN Jie,CHEN Shenxia,LING Luoya,et al.Invest igat ion on immunogenici ty and immunizat ion procedure of China-made live attenuated measles-mumpsrubella combined vaccine[J].Chinese Journal of Vaccines and Immunization,2006,12(3):215-217.
[6]储艳,陆玉忠,陶红,等.国产麻腮风联合减毒活疫苗的安全性及免疫原性[J].中国生物制品学杂志,2011,24(6):707-710.CHU Yan,LU Yuzhong,TAO Hong,et al.Saf ety and immunogenicity of domestic combined live attenuated measles,mumps and rubella vaccine[J].Chinese Journal of Biologicals,2011,24(6):707-710.
[7]邵茜,朱梦蓉,刘鹏,等.8月龄首剂接种国产麻疹腮腺炎风疹联合减毒活疫苗的安全性及免疫原性观察[J].预防医学情报杂志,2016,32(7):742-746.SHAO Xi,ZHU Mengrong,LIU Peng et al,et al.Saf ety and immunogenicity of domestic combined live attenuated measles,mumps and rubel la vaccine in jected wi th8-month infants at the first dose[J].Journal of Preventive Medicine Information,2016,32(7):742-746.
[8]刘国华,方悍华,冯子健,等.冻干麻疹-腮腺炎-风疹三联活疫苗免疫安全性及免疫学效果观察[J].中华流行病学杂志,2002,23(6):435-437.LIU Guohua,FANG Hanhua,FENG Zijian,et al.Studies on the saf ety and immunogenicity oflyophilized live attenuated measles-mumps-rubella combined vaccine[J].Chinese Journal of Epidemiology,2002,23(6):435-437.
[9]俞柳燕,陈深侠,凌罗亚,等.8月龄儿童接种麻疹-腮腺炎-风疹三联疫苗免疫效果及接种安全性观察[J].中国预防医学杂志,2008,9(3):206-207.YU Liuyan,CHEN Shen xia,LING Luoya,et al.Observat ion on immunizat ion ef fect and saf e ty of measles-mumps-rubella triple vaccine for children aged 8months[J].China Preventive Medicine,2008,9(3):206-207.
[10]徐福根,陈康凯,黄利明,等.麻腮风(MMR)疫苗初免效果和程序的研究[J].浙江预防医学,2000,12(11):1-3.XU Fugen,CHEN Kangkai,HUANG Liming,et al.Study on the primary immunization ef fect and procedure of measles-mumps-rubella(MMR)vaccine[J].Zhe jiang Journal of Preventive Medicine,2000,12(11):1-3.
[11]徐福根,许二萍,黄诚孝,等.不同月龄婴儿接种腮腺炎疫苗的免疫效果比较[J].中国生物制品学杂志,2000,13(2):71.XU Fugen,XU Er ping,HUANG Chengx iao,et al.Comparison ofimmune effects of mumps vaccination in infants of different months of age[J].Chinese Journal of Biologicals,2000,13(2):71.
[12]杨秀惠,吴根生,周勇,等.福建省流行性腮腺炎疫苗免疫效果分析及程序探讨[J].海峡预防医学杂志,2015,21(6):17-20.YANG Xiuhui,WU Gensheng,ZHOU Yong,et al.Analysis of the immunization effect of mumps vaccine in Fujian province and discussion on the procedure[J].St rai t Journal of Preventive Medicine,2015,21(6):17-20.
[13]JIN L,ORVELL C,MYERS R,et al.Genomic diversity of mumps virus and global distribution of the 12 genotypes[J].Reviews in Medical Virology,2015,25(2):85-101.
[14]RUBIN SA,LINK MA,SAUDER CJ,et al.Recent mumps outbreaks in vaccinated populat ions:no evidence ofimmune escape[J].Journal of Virology,2012,86(1):615.
[15]CUI A,RIVAILLER P,ZHU Z,et al.Evolutionary analysis of mumps viruses of genotype F collected in mainland China in 2001-2015[J].Scientific Repor ts,2017,7(1):17144.
[16]CUI A,ZHU Z,HU Y,et al.Mumps epidemiology and mumps virus genotypes circulating in mainland China during 2013-2015[J].PloS One,2017,12(1):e0169561.
[17]VAIDYA SR,DVIVEDI GM,JADHAV SM.Cr ossneutralization between three mumps viruses&mapping of haemagglutinin-neuraminidase(HN)epitopes[J].Indian Journal of Medical Research,2016,143(1):37-42.
[18]GOUMA S,TEN HULSCHER HI,TM SK,et al.Mumpsspecific cross-neutralization by MMR vaccine-induced ant ibodies predicts protect ion against mumps vi rus infection[J].Vaccine,2016,34(35):4166-4171.
[19]ATCHAREEYA AN,PRAKONG S,SA-NGASANG A,et al.Comparison between haemagglutination inhibition(HI)test and IgM and IgG-capture ELISA in determination of primary and secondary dengue virus infections[J].Dengue Bulletin,2006,30:141-145.
[20]陈康凯,闻洪根,王衡.腮腺炎抗体测定血凝抑制法与酶联法的比较[J].预防医学情报杂志,2001,17(3):205-206.CHEN Kangkai,WEN Honggen,WANG Heng.Comparison of hemagglutination inhibition assay and enzyme-linked assay for detection of mumps antibody[J].Journal of Preventive Medicine Information,2001,17(3):205-206.
[21]NURHAYATI L,GUSTIANI S,HERMAN K,et al.Comparison of the hemagglutination inhibition test and IgG ELISA in categorizing primary and secondary dengue infections based on the plaque reduction neutralization test[J].BioMed Research International,2016,2016(1):5253842.